INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that affects 10-30% of patients with psoriasis. 1 2 To date, genome-wide association studies (GWAS) as well as candidate gene studies have shown that both diseases share a substantial genetic component. However, sibling recurrence rates (λ s ) are much higher for PsA than psoriasis (PsA λ s ∼37 vs psoriasis λ s ∼7), [3] [4] [5] indicating that additional, perhaps disease-specific, risk factors need to be identified.
GWAS based on single-nucleotide polymorphisms (SNPs) have been highly successful in identifying >30 loci associated with psoriasis and PsA susceptibility. [6] [7] [8] The cumulative risk exerted by these loci, however, is <50%, 9 and additional genetic factors still need to be identified in order to explain the missing heritability. Strategies to complete the characterisation of the genetic architecture of psoriasis and PsA include the use of large sample sizes or the combination of different studies through metaanalysis, 10 the deep sequence characterisation to identify rare variants with large effect sizes 11 and, also, the analysis of other types of genetic variation that cannot be completely captured by SNP-based genotyping platforms such as copy number variants (CNVs).
CNVs are fragments of DNA with sizes that range from hundreds of bases to several megabases, and that can either be absent (ie, deletions), repeated a certain number of times (ie, amplifications) or even rearranged. 12 Psoriasis was one of the first chronic inflammatory diseases where CNVs were found to be associated with the disease risk. The amplifications of the β-defensin genes on 8p23.1 region 13 and the deletion affecting LCE3B and LCE3C genes 14 have been clearly associated with psoriasis aetiology. The association of these CNVs with PsA aetiology, however, is still not clear, 2 15 suggesting that they could participate in the chronic inflammatory processes in the skin rather than in the pathological process occurring in the joint.
In the present study, we have performed the first genomewide analysis of CNVs in PsA. We have first analysed a discovery panel of 835 patients with PsA and 1498 healthy controls from the Spanish population using a microarray platform. The CNVs showing a more significant association to PsA risk were subsequently selected and validated in an independent cohort of 1133 patients with PsA and 1831 healthy controls. In order to test for the specificity of the CNV association with PsA aetiology, we have also analysed a set of 822 psoriasis patients without arthritis. Using this approach, we have identified a new deletion associated with PsA risk that is not associated with purely cutaneous psoriasis (PsC).
PATIENTS AND METHODS Study subjects
To identify new loci associated with psoriasis risk using the GWAS approach, we recruited 835 patients with PsA and 1498 healthy controls from the Spanish population. Patient and control individuals were obtained by the Immune-Mediated Inflammatory Disease Consortium (IMIDC). 16 The IMIDC is a Spanish biomedical research collaboration project that includes biomedical and clinical researchers on rheumatology, dermatology and gastroenterology, and that is devoted to the study of prevalent autoimmune diseases. In the present study, a total of 26 rheumatology departments-15 in the GWAS stage and 11 additional in the replication stage-and 11 dermatology departments from different university hospitals in Spain participated in the patient recruitment and clinical data collection. All patients with PsA included in this study had a clinical diagnosis made by a consultant rheumatologist. All patients with PsA were diagnosed according to the Classification Criteria for Psoriatic Arthritis criteria, 17 were >18 years old-although the disease could have started earlier in life-and had at least 1 year of evolution of the disease. Exclusion criteria for the present study were (i) presence of any other inflammatory joint disease, (ii) presence of any inflammatory bowel disease and (iii) positivity of rheumatoid factor.
Control individuals for the GWAS stage were recruited from blood bank donors attending at 13 hospitals from different regions in Spain in collaboration with the Spanish National DNA Bank (http://www.bancoadn.org). Eligible individuals were screened for the presence of PsA or any other autoimmune disorder, as well as for history of autoimmune disorders in firstdegree relatives, and positive individuals were discarded from this study. Additionally, in order to increase the 'hypernormality' of the control cohort, 18 only individuals who were >30 years old were included. In total, 1498 controls, 40% of whom were women, were analysed in the GWAS. Of note, >96% of the control individuals were >40 years old at the time of recruitment.
All patients and controls in the GWAS and replication cohorts were Caucasian European. In those cases where any of the four grandparents was not born in Spain, the individual was discarded from the study. The DNA samples from patients and controls in both stages of the study were obtained from whole blood samples.
A total of 1131 patients with PsA and 1831 controls were used to validate the most significant loci identified in the GWAS phase. Both cohorts were collected using the same clinical and epidemiological selection criteria as for the GWAS. Additionally, a sample of 822 patients diagnosed with psoriasis and without PsA (ie, PsC) was also analysed in the validation phase. All patients with PsC were diagnosed and recruited by a consultant dermatologist participating in the IMID Consortium. 2 Psoriasis patients with plaque psoriasis affecting torso and/or extremities and with at least one year of duration were included. Patients with a single clinical localisation of plaque psoriasis (ie, scalp, face, palmoplantar), with exclusively inverse plaque psoriasis or with an inflammatory bowel disease, were excluded from the study. Finally, psoriasis patients diagnosed with PsA by a rheumatologist were excluded from this group.
Genome-wide CNV analysis
We performed a CNV genome-wide scan by using Illumina 610Quad Beadchips (Illumina, San Diego, California, USA), which contains a total of 620 901 probes. Sample genotyping was performed at the HudsonAlpha Institute for Biotechnology (Alabama, USA). After excluding mitochondrial as well as X and Y chromosome SNPs, a total of 600 470 probes were considered for GWAS CNV analysis. Before proceeding to perform PsA risk analysis, we performed several quality control analysis steps. First, only those samples that had a >95% genotype completion rate were considered for analysis (99% of samples). Second, we used the SNPs genotype information to estimate the main axes of variation using the principal component analysis implemented in the Eigenstrat software. 19 With this approach, individuals showing a high deviation in any of the 10 top principal axes of variation were considered outliers and were consequently removed (>6 SDs from the centre of each component, n=42 outliers). Online supplementary figure S1 shows the patient with PsA and control distributions according to the first and second principal components after excluding the outliers.
Since CNV genotyping is subject to more technical biases than SNP genotyping, several additional quality control filters must be applied to the GWAS data. Following previous GWAS CNV studies, 20 samples with a substantial deviation from the mean log Ratio (|m log R ratio| > 0.1) or with an excessive variability (σ log R ratio > 0.2), were excluded (n=556 individuals, 23.8%). After applying all the quality control filters, a total of 658 patients with PsA and 1063 controls were finally available for the CNV GWAS. Online supplementary figure S2 shows a schematic representation of the global CNV analysis workflow.
CNV identification and genotyping was performed using CNstream software (figure 1A). 21 CNstream first applies a normalisation procedure to control for the presence of potential intensity biases from samples processed at different time points (ie, batch normalisation). It then applies a second normalisation step to minimise the difference of sensitivity between the two colour channels used to analyse each probe (ie, intensity normalisation). 22 Once the data are normalised, CNstream jointly analyses sets of consecutive probes (n=5 in this study) to identify the presence of a CNV in a particular region of the genome and generate a genotype call for each individual.
After genome-wide CNV identification and calling, the association with disease risk was tested using the genotypic χ 2 test. In the case of low-frequency CNVs (minor allele frequency <5%), the genotype counts for CNV homozygous (0N) as well as individuals with 1 deletion (1N) were merged in a single CNV-positive group and compared with non-CNV carriers (2N). Statistical association analyses were performed using R software V.3.0.1. 23 
Targeted sequencing of ADAMTS9-MAGI1 locus
In order to characterise the chromosome 3q14.2 sequence harbouring the deletion associated with PsA risk in the CNV GWAS, we performed a targeted resequencing analysis in selected samples from the discovery phase. Next-generation sequencing was performed at the HudsonAlpha Institute for Biotechnology (Alabama, USA). A total of 100 patients with PsA and 100 control individuals were selected for sequencing of ADAMTS9-MAGI1 locus. The individuals were selected so that deletion carriers and non-carriers-as determined by GWAS genotyping-were equally present in both groups. Consequently, 100 sequenced individuals carried one or two deletions (ie, 1N or 0N) and 100 individuals had no deletion (ie, 2N individuals).
The Illumina sequencing platform (Illumina, San Diego, USA) was used to characterise the deletion sequence. In order to identify yet undiscovered variants in the two flanking genes that could be responsible for the observed association with PsA risk, we also sequenced ADAMTS9 and MAGI1 genes and their 5 0 and 3 0 flanking sequences. First, the DNA quality of these samples was assessed by running 1-3 mL on a 1% agarose gel that contained 1× Sybr Green I dye (Life Technologies, USA).
Next we followed the CATCH-Seq procedure we reported recently. 24 In brief, we purified CTD-2216H2, CTD-2255G2, CTD-2517E23, RP11-841H13, RP11-1080G20, RP11-411F5 and RP11-257J13 BAC DNAs that are commercially available (Life Technologies). BAC DNAs were pooled by percentage of the total target size (1.1 Mb) according to a 4 mg total input mass, and the pool was sheared by E220 Covaris sonication. Linkers containing T7 promoter sequences were ligated to sheared BAC fragments, and biotinylated RNA probes were synthesised by in vitro transcription using a MEGAscript kit (Ambion) and biotin-11-UTP (Life Technologies) with T7-BAC fragments as template. Illumina libraries were prepared according to standard protocol using 24 inline barcoded adapters. 
with frequent pulse vortexing. Bead captures were washed twice for 15 min each at room temperature in 0.5 mL wash buffer 1 (1×SSC, 0.1% SDS), followed by four stringency wash steps at 65°C in 0.5 mL preheated wash buffer 2 (0.1×SSC, 0.1% SDS) for 10 min each. Captured libraries were eluted in 50 μL 0.1 M NaOH and neutralised in
Sequencing reads from individual samples were demuxed based on inline barcode sequences and aligned to the human reference genome (hg19) with BWA. 25 Relative read depth was calculated as the number of bases mapped to 100 bp windows per total bases mapped for a given sample. Then a log2 ratio between each sample at each 100 bp window to the mean of all samples at that window was used to plot a normalised read depth, representing the read depth relative to a theoretical diploid reference. The plots of these normalised read depths across the locus were used to confirm the presence of the deletion (figure 1B).
CNV replication analysis
Replication genotyping was performed using the TaqMan Genotyping System (Applied Biosystems, Foster City, California, USA). Two pre-designed Taqman CNV assays Hs03225015_cn and Hs03225295_cn were found to be located within the estimated deletion boundaries. In order to validate the two assays, we genotyped the group of 200 individuals that were previously used to sequence the deletion. The correspondence between the calls of the two CNVs between the Taqman and sequencing analysis was 100%. Consequently, we used the two Taqman assays to genotype the ADAMTS9-MAGI1 deletion in an independent group of 1133 patients with PsA, 1831 healthy controls and 822 patients with PsC. Quality control measures similar to the GWAS were applied, including genotyping call rate >95%, sample completion rate >90% and Hardy-Weinberg disequilibrium p value of control group p>0.001. The CNV genotype concordance between the two Taqman assays was >99%. Meta-analysis of the GWAS and replication association statistics was performed using METAL software. 26 Table 1 summarises the main features of the GWAS and replication PsA patient cohorts.
RESULTS

CNV identification and genotyping
Using a total of 658 patients with PsA and 1063 healthy controls, we identified a total of 2674 CNV segments. After merging segments belonging to the same genomic region (distance <10 kb and/or r 2 >0.9), we performed the genotype calling in a total of 1953 different CNV regions. Among them, 165 CNVs appeared in >5% of the samples and were subsequently used to test for association with PsA risk. Online supplementary table S1 describes the characteristics of these CNVs.
CNV GWAS for PsA risk
Using the group of common CNVs, we performed a GWAS for PsA risk. We found a very strong association signal at an intergenic deletion located between the HLA-C and HLA-B genes (p=5.37e-11, OR (95% CI) 2.08 (1.47 to 2.95), MAF=0.18, figure 2 ). Since HLA-C locus is an established risk locus for PsA we sought to estimate the association of the deletion after correcting for the HLA haplotypes associated with psoriasis risk as recently described. 27 We found that, after correcting for HLA-C*0602 and HLA-B*3801 alleles, the deletion was no longer associated with PsA risk (p=0.81, see online supplementary table S2). Consequently, this CNV was considered a proxy for the HLA allele association and was not included for replication.
We also found another highly significant association for a deletion located in the chromosome 3q14.2 intergenic region, between ADAMTS9 and MAGI1 genes ( p=0.00014, OR (95% CI) 1.94 (1.37 to 2.75), MAF=0.04, figure 2 ). This genomic region had not been previously associated to any SNP-based Figure 2 Plot of the copy number variant (CNV) genome-wide association studies results. The −log10 p values (y-axis) are plotted for each of the CNVs identified by CNSstream. Each chromosome is coded in a different colour. The probes mapping the intergenic deletion in HLA-C/-B locus in chromosome 6 (light blue dots) were found to have a high significance; however, after correcting for HLA-C and HLA-B alleles this association disappeared. In chromosome 3, an intergenic deletion between genes ADAMTS9 and MAGI1 ( purple dot) shows a significant association that withstands multiple test correction. GWAS in PsA or any other related disease. After correcting for the number of CNVs analysed, the deletion association was still found to be significantly associated with PsA risk ( p=0.023, Bonferroni multiple test correction). Consequently, we selected this region for replication in the independent data set of patients and controls. In the remaining group of CNVs, we found 12 additional CNV regions nominally associated with PsA risk ( p<0.05, see online supplementary table S3). However, after multiple test correction none of these variants was statistically significant and therefore they were not selected for replication. Additionally, evaluating the concordance between these CNVs and neighbouring SNPs, we did not find a strong linkage disequilibrium (LD) (r 2 >0.8) with markers previously associated with PsA, Ps or other autoimmune diseases.
CNV replication in the validation cohorts
The deletion genotypes determined using the quantitative RT-PCR assays showed a 100% concordance with the number of copies (0, 1 or 2) estimated using sequencing. We subsequently used these two RT-PCR assays to genotype an independent cohort of 1133 patients with PsA and 1831 controls. We replicated the association of the ADAMTS9-MAGI1 intergenic deletion with PsA risk ( p=0.032, OR (95% CI) 1.3 (1.0 to 1.7), meta-analysis p=5.97e-5, OR (95% CI) 1.48 (1.21 to 1.82)).
Finally, comparing the frequencies of ADAMTS9-MAGI1 deletion of patients with PsA with patients with PsC, we also found a statistically significant increase of the deletion in the group of patients with PsA similar to that observed when comparing to healthy controls (freq PsA=11.0%, freq PsC=7.7%, freq controls=8.8%, p=0.0088). Accordingly, when comparing patients with PsC to healthy controls, we did not find a statistically significant difference between the deletion frequencies of groups ( p=0.33).
ADAMTS9-MAGI1 deletion sequence characterisation
Using a next-generation sequencing approach, we characterised the deletion region in chromosome 3q14.2 associated with PsA risk. Using a sample of 100 patients with PsA and 100 controls selected to have a higher frequency of the deletion (in total, 100 deletion carriers vs 100 2N individuals), we determined the physical extent and molecular nature of ADAMTS9-MAGI1 deletion polymorphism. PCR capture and sequencing of the deletion breakpoints revealed that the deletion removes 25 879 nucleotides ( figure 1D) .
In order to explore the LD pattern associated with the deletion and the relation with the two flanking genes, we sequenced ADAMTS9 and MAGI1 genes and their proximal 5 0 and 3 0 untranslated regions. LD analysis showed clearly that only very few close polymorphisms have moderate to high correlation with the deletion (r 2 >0.7, n=2 0 SNPs, figure 3) . From the >18 000 DNA variants identified after sequencing both ADAMTS9 and MAGI1 genes, none showed a significant LD with the deletion (figure 3).
DISCUSSION
GWAS based on SNPs have been highly successful in identifying genetic variants associated with the risk to develop psoriasis and PsA. However, there is still a large fraction of the genetic basis of PsA that has not been identified. In the present study, we have performed a GWAS of CNVs to identify new genomic loci associated with PsA risk. Using a discovery cohort of Spanish patients with PsA and controls, we have found a significant association of a deletion located between ADAMTS9 and MAGI1 genes with PsA risk. We have subsequently validated this association in an independent cohort of patients and controls. Furthermore, using a cohort of patients with psoriasis without concomitant arthritis we provide evidence that the deletion is specific for PsA.
ADAM metallopeptidase with thrombospondin type 1 motif 9 (ADAMTS9) gene belongs to a family of enzymes specialised in the degradation of the extracellular matrix. In particular, ADAMTS9 belongs to the family of the aggrecanases (which also includes ADAMTS-1, ADAMTS-4, ADAMTS-6, ADAMTS-8 and ADAMTS-15) that are specialised in the degradation of aggrecan, one of the main proteoglycan constituents of the cartilage extracellular matrix. 28 Aggrecanase activity has been found to be associated with cartilage degradation in inflammatory joint diseases including PsA. 29 30 Importantly, in vitro studies with chondrocytes have found that after stimulation with tumour necrosis factor (TNF)-α and interleukin (IL)-1, two of the most abundant cytokines in PsA synovium, ) between the deletion and the >18 000 variants identified after sequencing the regions flanking the copy number variants as well as ADAMTS9 and MAGI1 loci. From these results, it is clear that only a small proportion of close variants show a high correlation with the deletion (ie, r 2 >0.9, centre region of the plot) and that there is no variant within the transcribed or the flanking regions of ADAMTS9 (left region) or MAGI1 (right region) that could explain the observed association. The 3p14.1 chromosome regions between these three loci and that were not sequenced are left blank.
ADAMTS9 was clearly the most highly induced among all the different aggrecanases. 32 33 Consequently, genetic variants that influence the rates of matrix turnover in the cartilage and bone of the inflamed synovial joint could be crucial in determining the level of tissue degradation in PsA.
Membrane-associated guanylate kinase, WW and PDZ domain containing 1 (MAG1) is a member of the membrane-associated guanylate kinase family of genes. MAGI1 is known to be expressed in cell-to-cell contacts, acting as a scaffold protein to stabilise cadherin-mediated adhesions and has been found to be expressed in epithelial and endothelial tight junctions. 34 MAGI1 activity has been related to several pathological junctionassociated processes, including oncogenic 35 as well as virusassociated invasiveness. 36 To date, there is no evidence of a direct implication of MAGI1 in PsA pathology or, even, in autoimmune diseases. There is evidence, however, that MAGI1 interacts with phosphatase and tensin homologue protein, a signalling protein that participates in the negative regulation of regulatory T cells (Tregs), 37 which are master inhibitors of autoimmunity. While the implication of Treg has been clearly defined in rheumatoid arthritis or psoriasis aetiology, 38 there are yet no studies directly analysing the implication of this key immune regulator in PsA, 39 although there is recent evidence of their activity in the disease pathology. 40 Clearly, future studies aimed at characterising the implication of MAGI1 activity in autoimmunity are necessary.
The deep sequence analysis found that there is very little correlation between the ∼26 kb intergenic deletion associated with PsA risk and the polymorphisms located in the transcribed sequences and proximal regions of ADAMTS9 and MAGI1 genes. Also, our sequencing analysis clearly shows that very few neighbouring markers are in moderate or high LD with this CNV, suggesting that the deletion itself is the genetic variant implicated in the aetiology of PsA. Exploration of the chromosome 3q14.2 deleted region in multiple biomedical databases including ENCODE 41 did not show regulatory evidence associated with this variation. Also analysing available cis and trans-eQTL regulatory data sets 42 we did not find an association between this deletion and the expression of other genes. However, it is increasingly becoming evident that a large fraction of regulatory variants in the genome will be only detected under the specific target tissue where they are expressed and, perhaps, only under the adequate stimulation. 43 For example, ADAMTS9 expression in chondrocytes was found to be expressed only after stimulation by proinflammatory cytokines TNF and IL-1. 32 Additional studies aimed at characterising the functional implications of this deletion and their role in PsA aetiology are therefore warranted.
To date, there is evidence that the frequency and penetrance of multiple risk loci in PsA and psoriasis risk is different populations with different ancestries. 44 It will be therefore necessary to evaluate the frequency and effect size of this deletion at 3p14.2 in other non-Caucasian populations. Also, the association of the ADAMTS9-MAGI1 CNV with different PsA phenotypes could be of high relevance. In our discovery cohort, we analysed the association of the deletion with axial disease, arthritis mutilans, gender, age of start of the disease and PsA familial aggregation, but we did not find a significant association (data not shown). These results support that the deletion at chromosome 3q14.2 is specifically associated to the risk to develop PsA. It is possible, however, that once the specific biological mechanisms influenced by this genetic variation are identified, more targeted analysis will reveal association to other PsA phenotypes.
In the present study, we have performed the first CNV GWAS in PsA. We have identified a new deletion in ADAMTS9-MAGI1 locus associated with PsA risk and we have validated this association in an independent patient and control cohort. Additionally, using a cohort of patients with PsC we have demonstrated that the variation is specifically associated with the development of PsA. The present study represents an important step in the characterisation of the common genetic variation associated with PsA.
